Medtronic Plc (NYSE:MDT) unveiled its
fiscal Q1 2026 financial results, reporting a rise in
profit as a result of increased
sales. The medical device powerhouse has seen significant
revenue growth, prompting it to raise its
Full-Year EPS guidance. Despite these strong results, the share price dipped post-announcement, against a generally strong market. Medtronic's recent
Q1 earnings were received positively by
analysts, leading to a potential revision of their forecasts. Major changes are being made to the board, as the company responds to a
large stake acquired by Elliott Management, a prominent investor. The company is expanding its board with new directors and creating special committees to spearhead
strategic initiatives. Additionally, Medtronic is prepared for further
divestitures and a potential spin-off of its
Diabetes Business, according to industry analysts. A standout in
healthcare, Medtronic is seen as a safe
dividend stock, announcing a cash dividend for the second quarter of fiscal year 2026. Wells Fargo, Citigroup, and Mizuho have all raised the price targets for MDT, indicating a generally
bullish outlook.
Medtronic Plc MDT News Analytics from Wed, 05 Feb 2025 08:00:00 GMT to Sat, 23 Aug 2025 17:10:11 GMT -
Rating 7
- Innovation 5
- Information 8
- Rumor -3
